Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine

JA Carcillo, WA Herzer, Z Mi, NJ Thomas and EK Jackson

Department of Anesthesiology/Critical Care Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA.

We recently reported that pretreatment with the type IV phosphodiesterase inhibitor Ro 20-1724 attenuates the development of endotoxin-induced acute renal failure in rats. Norepinephrine is an important therapeutic agent in human endotoxemia, but its efficacy is limited by its deleterious side effect of potent renal and mesenteric vasoconstriction. In this study we examined whether posttreatment with Ro 20-1724 after endotoxin infusion 1) attenuates increased renal vascular resistance and the development of acute renal failure in the absence and presence of norepinephrine infusion, 2) improves mesenteric blood flow in the presence of norepinephrine and 3) improves survival rates in the absence and presence of norepinephrine infusion. Forty- eight rats were anesthetized and instrumented, and eight 20-min clearance periods were performed. Endotoxin (20 mg/kg i.v.) was administered after the first period, and a constant-rate i.v. infusion of either Ro 20-1724 (10 micrograms/kg/min) or vehicle was initiated after period 3, in the absence and presence of norepinephrine infusion (1 microgram/kg/ min, begun after period 4). Urinary cAMP excretion in the Ro 20-1724-treated groups was 2- to 3-fold (P < .001) higher, compared with the vehicle-treated groups. Ro 20-1724 markedly attenuated endotoxin-induced (P < .01) increases in renal vascular resistance and attenuated norepinephrine-induced (P < .05) increases in renal vascular resistance in rats pretreated with endotoxin. Moreover, Ro 20-1724 reduced endotoxin-induced decreases in renal blood flow (P < .05) and glomerular filtration rate (P < .01) in the absence and presence of norepinephrine. In animals pretreated with endotoxin, Ro 20- 1724 attenuated norepinephrine-induced increases in mesenteric vascular resistance (P = .054) and decreases in mesenteric blood flow (P < .01). Ro 20-1724 also improved survival rates for endotoxin-treated rats, whether or not the rats were administered norepinephrine (P < .01). Type IV-specific phosphodiesterase inhibitors warrant further study as selective therapeutic agents that protect against endotoxin/vasopressor- induced renal and mesenteric ischemia and death.

Volume 279, Issue 3, pp. 1197-1204, 12/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Cheng and J. P. Grande Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease Experimental Biology and Medicine, January 1, 2007; 232(1): 38 - 51. [Abstract] [Full Text] [PDF]

				H. T. Lee and C. W. Emala Preconditioning and Adenosine Protect Human Proximal Tubule Cells in an In Vitro Model of Ischemic Injury J. Am. Soc. Nephrol., November 1, 2002; 13(11): 2753 - 2761. [Abstract] [Full Text] [PDF]

				T. E. N. Jonassen, M. Grabe, D. Promeneur, S. Nielsen, S. Christensen, and N. V. Olsen Lipopolysaccharide-Induced Acute Renal Failure in Conscious Rats: Effects of Specific Phosphodiesterase Type 3 and 4 Inhibition J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 364 - 374. [Abstract] [Full Text] [PDF]

				N. J. Thomas, J. A. Carcillo, W. A. Herzer, Z. Mi, and E. K. Jackson Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 168 - 174. [Abstract] [Full Text]

				H. T. Lee and C. W. Emala Adenosine attenuates oxidant injury in human proximal tubular cells via A1 and A2a adenosine receptors Am J Physiol Renal Physiol, May 1, 2002; 282(5): F844 - F852. [Abstract] [Full Text] [PDF]